1. Impact of immunosuppressive drugs on efficacy of mesenchymal stem cell therapy for suppressing renal fibrosis.
- Author
-
Miyasako K, Nakashima A, Ishiuchi N, Tanaka Y, Morimoto K, Sasaki K, Nagamatsu S, Matsuda G, and Masaki T
- Subjects
- Animals, Mice, Male, Cyclosporine pharmacology, Interferon-gamma metabolism, Kidney Diseases therapy, Cyclophosphamide pharmacology, Methylprednisolone pharmacology, Kidney pathology, Kidney drug effects, Kidney metabolism, Disease Models, Animal, Mice, Inbred C57BL, Humans, Mesenchymal Stem Cell Transplantation methods, Fibrosis, Immunosuppressive Agents pharmacology, Immunosuppressive Agents therapeutic use, Mesenchymal Stem Cells metabolism, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells drug effects
- Abstract
Preemptive regenerative medicine using mesenchymal stem cells (MSCs) may provide a novel therapeutic approach to prevent the progression from organ damage to organ failure. Although immunosuppressive drugs are often used in patients with organ disorder, their impact on MSC therapy remains unclear. We investigated the effects of immunosuppressive drugs on the therapeutic efficacy of MSCs. We created unilateral ureteral obstruction models, as a well-established model of renal fibrosis, a preliminary stage of organ failure. Three immunosuppressive drugs (methylprednisolone, cyclosporine, and cyclophosphamide) were intraperitoneally administered 3 days after surgery, and MSCs were injected via tail vein the following day. Preadministration of methylprednisolone or cyclophosphamide interfered with MSC activation by reducing expression of interferon-gamma (IFN-γ) and high-mobility group box-1 protein, thus significantly attenuating the therapeutic efficacy of MSCs. Preadministration of cyclophosphamide downregulated the expression of stromal cell-derived factor-1/C-X-C motif ligand 12, which is a potent migration factor for MSCs, resulting in reduced MSC engraftment in the renal cortex. IFN-γ-preconditioned activated MSCs were unaffected by these drugs and maintained their beneficial therapeutic effects. Cyclosporine preadministration had no effect on the therapeutic efficacy of MSCs. Our study demonstrated that the administration of certain immunosuppressive drugs interfered with MSC activation and engraftment at the site of injury, resulting in a significant attenuation of their therapeutic efficacy. These findings provide crucial information for selecting patients suitable for MSC therapy. Use of MSCs preactivated with IFN-γ or other means is preferred for patients on methylprednisolone or cyclophosphamide., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF